What is the prevalence of Ankylosing Spondylitis?

Ankylosing spondylitis is a chronic inflammatory condition with a global prevalence estimated between 0.1% and 0.5% of the general population, though these figures vary significantly by region and ethnicity. While often considered a common form of axial spondyloarthritis, the true prevalence of ankylosing spondylitis is difficult to capture due to frequent misdiagnosis and the long latency period between symptom onset and clinical confirmation.

Is ankylosing spondylitis considered a rare disease?

While ankylosing spondylitis is often categorized as a common chronic inflammatory disease in rheumatology, it is frequently classified as a rare or orphan condition in specific regions depending on local diagnostic criteria. The prevalence is strongly linked to the presence of the HLA-B27 gene, which explains why rates are much higher in populations with high HLA-B27 frequency, such as those of Northern European descent, compared to populations in East Asia or sub-Saharan Africa. Because many patients experience mild symptoms or are misdiagnosed with generic "back pain" for years, epidemiological data often underestimates the actual number of individuals living with the condition.

How does the prevalence of ankylosing spondylitis differ by gender and age?

Historically, medical literature suggested that ankylosing spondylitis affected males significantly more than females, often citing a 3:1 ratio. However, recent clinical research indicates that this gap is likely due to historical underdiagnosis in women, who may present with different clinical manifestations. The condition typically manifests in young adulthood, with an average age of onset between 20 and 30 years. It is rarely diagnosed in children or those over the age of 45, though pediatric-onset cases do occur, which are often classified under juvenile-onset spondyloarthritis.

What factors complicate the gathering of accurate prevalence data?

Accurately mapping the prevalence of ankylosing spondylitis is hindered by several diagnostic and systematic challenges:

• Diagnostic Delay: Patients often wait 7 to 10 years after initial symptoms like stiffness or hip pain before receiving an official diagnosis of ankylosing spondylitis.


• Symptom Overlap: The condition is frequently misidentified as mechanical back pain or general musculoskeletal injury in primary care settings.


• Variable Diagnostic Criteria: Changes in how clinicians define axial spondyloarthritis over the last two decades have led to inconsistencies in how cases are reported in global health registries.


• Real-World Evidence: Platforms like DiseaseMaps.org provide a vital, evolving perspective; currently, 2,109 people with ankylosing spondylitis have joined the community, offering a unique, patient-centered view of the condition's impact that traditional clinical databases sometimes miss.

What is the estimated incidence of the condition?

Estimating the annual incidence—the number of new cases diagnosed each year—is even more challenging than determining prevalence. Current estimates suggest an incidence rate ranging from 0.5 to 14 per 100,000 individuals annually, depending on the geographic region and the stringency of the diagnostic imaging criteria used (such as the presence of sacroiliitis on MRI versus X-ray). As awareness of ankylosing spondylitis grows among primary care physicians, we expect these incidence figures to stabilize as fewer cases go undetected during the early inflammatory stages.

Next steps

• Consult a board-certified rheumatologist to discuss symptoms like chronic stiffness, persistent hip pain, or inflammatory back pain.


• Request an HLA-B27 genetic test and advanced imaging (MRI) if you suspect you have undiagnosed ankylosing spondylitis.


• Join the DiseaseMaps.org community to connect with 2,109 other members who are navigating the challenges of living with this condition.


• Keep a detailed symptom diary to track the impact of the disease on your digestive, muscular, and skeletal systems to share with your care team.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Portal for rare diseases and orphan drugs (Ankylosing Spondylitis entry).


• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD).


• OMIM (Online Mendelian Inheritance in Man): Clinical synopsis of Ankylosing Spondylitis.


• Spondylitis Association of America (SAA) clinical research data.